U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901751) titled 'Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)' on Oct. 21.

Brief Summary: The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Retinitis Pigmentosa (RP) Inherited Retinal Diseases

Intervention: DRUG: RTx-015

Intravitreal injection

OTHER: Sham Control

Sham Control

Recruitment Status: RECRUITING

Sponsor: Ray Therapeutics, Inc.

Publish...